Swedish Orphan Biovitrum
376,60 SEK
-1,21 %
Mindre end 1K følgere
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Værdiansættelse
Resultatopgørelse
Kvartalsdata
Resultatopgørelse
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Swedish Orphan Biovitrum
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Omsætning | 14.248,0 | 15.261,0 | 15.529,0 | 18.790,0 | 22.123,0 | 26.027,0 | 28.238,0 |
| vækst-% | 7,1 % | 1,8 % | 21,0 % | 17,7 % | 17,6 % | 8,5 % | |
| EBITDA | 5.934,0 | 6.841,0 | 5.739,0 | 6.232,0 | 7.266,0 | 9.304,0 | 10.963,0 |
| EBIT | 4.533,0 | 4.818,0 | 3.733,0 | 3.813,0 | 4.066,0 | 5.625,0 | 867,0 |
| Overskud før skat | 4.247,0 | 4.217,0 | 3.295,0 | 3.321,0 | 2.954,0 | 4.407,0 | 34,0 |
| Netto indkomst | 3.304,0 | 3.245,0 | 2.679,0 | 2.638,0 | 2.409,0 | 3.879,0 | 476,0 |
| EPS | 10,78 | 10,53 | 8,69 | 8,52 | 7,47 | 11,37 | 1,39 |
| Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Udbytte ratio | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Lønsomhed og afkast på kapital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 41,6 % | 44,8 % | 37,0 % | 33,2 % | 32,8 % | 35,7 % | 38,8 % |
| EBIT-% | 31,8 % | 31,6 % | 24,0 % | 20,3 % | 18,4 % | 21,6 % | 3,1 % |
| ROE | 19,5 % | 16,1 % | 11,5 % | 9,9 % | 7,1 % | 9,6 % | 1,3 % |
| ROI | 7,2 % | 6,7 % | 5,5 % | 5,0 % | 3,3 % | 5,1 % | 0,7 % |